Ken Griffin Cyclo Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 24,670 shares of CYTH stock, worth $18,255. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,670Holding current value
$18,255% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding CYTH
# of Institutions
23Shares Held
2.24MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA817KShares$604,7790.39% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$355,72372.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA447KShares$330,4640.0% of portfolio
-
Geode Capital Management, LLC Boston, MA175KShares$129,8090.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$81,417100.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $6.25M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...